相关实验视频

Updated: Jan 11, 2026

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

开发一种方法来评估植物药物的心脏毒性潜力

Julie Krzykwa¹, Hemantkumar S Chaudhari², Andre Monteiro Da Rocha³

¹Health and Environmental Sciences Institute, Washington, DC, United States.

Frontiers in toxicology

|November 17, 2025

概括

植物产品缺乏广泛的安全测试. 新方法方法 (NAMs) 提供创新的,与人类相关的方法来评估心脏毒性,改善植物性消费品的安全评估.

科学领域:

毒理学毒理学毒理学
心血管研究研究心血管研究
植物科学植物科学

背景情况:

植物性药物广泛用于健康益处,但往往缺乏严格的市场前毒性测试.
评估植物性心脏毒性是具有挑战性的,因为复杂的混合物和变异性.
尽管心脏不良事件很少发生,但强调了需要进行强有力的安全评估的必要性.

研究的目的:

概述植物安全联盟 (BSC) 心脏毒性工作组评估新方法方法 (NAM) 的策略.
确定和完善用于评估植物产品潜在心脏毒性的NAM.
推进NAM在监管毒理学中的应用,以促进植物安全.

主要方法:

使用*体外*模型,包括人类诱导的多能干细胞衍生的心肌细胞.
采用诸如微电极阵列,电压和光学映射,收缩力测量和线粒体功能测试等技术.
将这些NAM应用于具有良好特征的植物提取物作为案例研究.

主要成果:

美国植物科学委员会正在开发一种工具包,用于植物产品的高通量,人体相关的心脏毒性查.
该方法利用先进的实验室测试来评估植物对心血管功能的影响.
这项工作为改善植物安全评估实践奠定了基础.

结论:

NAM为评估植物性心脏毒性提供了高效,具有成本效益和与人类相关的解决方案.
BSC的工作旨在加强广泛消费植物产品的安全评估.
精制的NAM将支持监管毒理学,并提高消费者安全.

关键词:

植物安全联盟的植物安全联盟.植物植物的植物.心脏有毒性心脏有毒性复杂的混合物复杂的混合物在体外 (in vitro) 的情况下.新方法的方法新方法的方法.

更多相关视频

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

相关概念视频

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...